Biopharmaceutical company, Biocon Biologics India has acquired some assets from Pfizer Healthcare to set up its second research and development (R&D) plant in India.
The assets have been acquired by Biocon Biologics India, a subsidiary of the Bengaluru-based company, for an undisclosed amount to set up a 60,000 sq ft state-of-the-art R&D facility in Chennai, Tamil Nadu.
The high-end integrated R&D facility in Chennai will enable Biocon Biologics India to expand its R&D capability and accelerate its journey towards meeting its strategic long-term goal of addressing the needs of millions of patients worldwide.
Currently, Biocon Biologics India has a 2,00,000 sq ft R&D centre at Bengaluru which has a product pipeline of 28 molecules, including 11 with Mylan, few with Sandoz and rest on its own. This investment will allow the company to fast-forward development of its biosimilars from bench to pilot scale.
Once operational, the facility is expected to house over 250 scientists who will have access to the R&D labs equipped with over 500 high-end process and analytical instrumentation.